Drugs / DYMISTA®
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DYMISTA | — | 2012-05-01 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02883439 | Aug 2016 → Mar 2020 | — | University Hospital, Ghent | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05684380 Comparator | Sep → Nov 2024 | allergic rhinitis | EMS | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DYMISTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05684380 ↗ |
| Known as | MP29-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02883439 ↗ |
| Route | Intranasal | “local nasal application” NCT02883439 ↗ |